Profile
Sector:
HealthcareCountry:
United StatesIPO:
03 May 2000Website:
http://cyclotherapeutics.comNext earnings report:
14 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 20:54:57 GMTDividend
Analysts recommendations
Institutional Ownership
CYTH Latest News
MILWAUKEE , Aug. 23, 2024 /PRNewswire/ -- Ademi LLP is investigating Cyclo Therapeutics (Nasdaq: CYTH) for possible breaches of fiduciary duty and other violations of law in its transaction with Rafael Holdings. Click here to learn how to join our investigation https://www.ademilaw.com/case/cyclo-therapeutics-inc or call Guri Ademi toll-free at 866-264-3995.
NEW YORK , Aug. 22, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Cyclo Therapeutics, Inc. (Nasdaq: CYTH), relating to its proposed merger with Rafael Holdings, Inc. Under the terms of the agreement, Cyclo common stock will automatically be converted into the right to receive shares of Rafael common stock.
Cyclo Therapeutics, Inc. (CYTH) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.33 per share a year ago.
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced the last patient has been enrolled in the Company's pivotal Phase 3 study (“TransportNPC™”) evaluating Trappsol® Cyclo™ for the treatment of systemic and neurological symptoms of Niemann-Pick Disease.
Cyclo Therapeutics, Inc. (Nasdaq: CYTH), a biotechnology company focused on developing transformative medicines for patients with diseases, announced its financial results for the first quarter of 2024 and gave an update on its business activities, including advancements in patient enrollment for the TransportNPC™ trial.
What type of business is Cyclo Therapeutics?
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.
What sector is Cyclo Therapeutics in?
Cyclo Therapeutics is in the Healthcare sector
What industry is Cyclo Therapeutics in?
Cyclo Therapeutics is in the Drug Manufacturers - Specialty & Generic industry
What country is Cyclo Therapeutics from?
Cyclo Therapeutics is headquartered in United States
When did Cyclo Therapeutics go public?
Cyclo Therapeutics initial public offering (IPO) was on 03 May 2000
What is Cyclo Therapeutics website?
https://cyclotherapeutics.com
Is Cyclo Therapeutics in the S&P 500?
No, Cyclo Therapeutics is not included in the S&P 500 index
Is Cyclo Therapeutics in the NASDAQ 100?
No, Cyclo Therapeutics is not included in the NASDAQ 100 index
Is Cyclo Therapeutics in the Dow Jones?
No, Cyclo Therapeutics is not included in the Dow Jones index
When was Cyclo Therapeutics the previous earnings report?
No data
When does Cyclo Therapeutics earnings report?
The next expected earnings date for Cyclo Therapeutics is 14 November 2024